Skip to main content

Recent Grants

Recent Grants

The Institute and the CNDD core facilities have been instrumental in developing public and private partnerships and have played a key role developing and submitting cross-disciplinary grant applications to federal agencies. These grant applications focus on nanomedicine technologies, including the successful Carolina Center of Cancer Nanotechnology Excellence (CCNE) and establishment of the Carolina Cancer Nanotechnology Training Program (C-CNTP).

Edward Moreira Bahnson, Ph.D.

  1. Cell-Mediated Targeted Redox Intervention for the Prevention of Restenosis in the Injured Vasculature
    CTSA KL2, 05/01/2017—04/30/2020; Role: PI
  2. Cell-Mediated Targeted Redox Intervention for the Treatment and Prevention of Atherosclerosis
    K01HL145354
    NHLBI, 12/15/2019 – 11/30/2023; Role: PI

Elena Batrakova, Ph.D.

  1. Cell-Based Platform for Gene Delivery to the Brain
    R01NS102412
    NINDS, 03/01/2018 – 11/30/2022; Role: PI
  2. Develop and Evaluate Efficacy of Nanoformulated Sibeclin1 Delivered Intranasally to Eliminate HIV in Brain
    R21MH118985
    NIMH, Florida International University, 03/13/2019 – 02/28/2021; Role: Co-Investigator
  3. Extracellular Vesicles for CNS Delivery of Therapeutic Enzymes to Treat Lysosomal Storage Disorders
    R01NS112019
    NINDS, 09/01/2019 – 06/30/2024; Role: PI

Zongchao Han, M.D., Ph.D.

  1. Targeting Retinitis Pigmentosa Using Nanoparticle-Mediated Delivery of Genomic DNA
    R01EY026564
    NEI, 04/01/2016 – 03/31/2021; Role: PI
  2. Targeting and Delivering CAR-Ts in Glioblastoma
    R21CA229938
    NCI, 04/01/2019 – 03/31/2021; Role: Co-Investigator
  3. Developing Novel Nano Antioxidants for the Treatment of Age-Related Macular Degeneration
    Edward N. & Della L. Thome Memorial Foundation, 05/01/2019 – 04/30/2021; Role: PI
  4. Selective Targeting Reactive Oxygen Species for Age-Related Macular Degeneration
    M2019063
    BrightFocus Foundation, 07/01/2019 – 06/30/2021; Role: PI

Alexander Kabanov, Ph.D., Dr.Sci.

  1. PEGylated Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
    R01CA184088
    NCI, 1/01/2015 – 12/31/2019; Role: PI
  2. Carolina Cancer Nanotechnology Training Program (C-CNTP)
    T32CA196589
    NCI, 7/01/2015 – 6/30/2020; Role: Director
  3. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    U01CA198910
    NCI, 8/14/2015 – 7/31/2020; Role: PI
  4. Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
    U54CA198999
    NCI, 9/01/2015 – 7/31/2020; Role: PI
  5. Nanoformulation of the BDNF for the Treatment of Stroke
    R21NS088152
    NINDS, 09/15/2015 – 8/31/2018; Role: PI
  6. Targeted Magneto-Mechanic Nanotherapeutics for Cancer
    R21CA220148
    NCI, 8/1/2017 – 7/31/2020; Role: PI
  7. Systemic Targeting of Mononuclear Phagocytes for Parkinson’s Disease Gene Therapy
    Eshelman Institute for Innovation, 06/01/2017 – 05/31/2020; Role: PI
  8. Nanoparticle Delivery of Cas9 and Therapeutic gRNAs to the Brain
    Eshelman Institute for Innovation, 06/01/2018 – 05/31/2020; Role: PI
  9. Targeting of Inflamed Monocytes for Gene Therapy of Cancer
    Eshelman Institute for Innovation, 06/01/2019 – 05/31/2020; Role: PI
  10. Targeting Tumor Associated Fibroblasts to Enhance Therapy
    Eshelman Institute for Innovation, 06/01/2019 – 05/31/2021; Role: Co-Investigator

Melina Kibbe, M.D.

  1. Targeted, Niche-Responsive Peptide Amphiphile Nanofibers as Injectable Drug Delivery Vehicles to Treat Atherosclerosis
    18POST33960499
    American Heart Association, 07/01/2018—06/30/2020; Role: PI
  2. A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ
    R01HL129156
    NHLBI, 01/01/2019 – 12/31/2022; Role: PI
  3. Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention
    R01GM130590
    NIGMS, 02/01/2019 – 11/30/2022; Role: Co-Investigator
  4. Development of Injectable, Niche-Responsive Peptide Amphiphile Nanofibers to Reduce Atherosclerotic Plaque Burden
    Burroughs Wellcome Fund, 06/01/2019 – 12/31/2020; Role: PI

Marina Sokolsky, Ph.D.

  1. Targeted Magneto-Mechanic Nanotherapeutics for Cancer
    R21CA220148
    NCI, 8/1/2017 – 7/31/2020; Role: Co-Investigator
  2. BCL-xL-regulated Apoptosis in Cerebellar Development and Medulloblastoma Treatment
    R01NS102627
    NINDS, 06/01/2018 – 04/30/2023; Role: Co-Investigator

Shaomin Tian, Ph.D.

  1. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator

Nick Tsihlis, Ph.D.

  1. A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ
    R01HL129156
    NHLBI, 01/01/2019 – 12/31/2022; Role: Co-Investigator

Andrew Wang, M.D.

  1. Carolina Cancer Nanotechnology Training Program (C-CNTP)
    T32CA196589
    NCI, 7/01/2015 – 6/30/2020; Role: Co-Director
  2. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    U01CA198910
    NCI, 08/14/2015 – 07/31/2020; Role: Co-Investigator
  3. Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy
    U54CA198999
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  4. Automatic Pelvic Organ Delineation in Prostate Cancer Treatment
    R01CA206100
    NCI, 09/01/2016 – 07/31/2021; Role: Co-Investigator
  5. Nanoscintillator-Based X-ray Sensitizers to Enable Efficient Non-Small Cell Lung Cancer Treatment with X-ray Irradiation
    R01EB022596
    NIBIB, University of Georgia, 03/15/2017 – 01/31/2019; Role: Co-Investigator
  6. Targeting through Selective Cell Labeling
    R01EB025651
    NIBIB, University of Illinois at Urbana-Champaign, 08/15/2018 – 04/30/2022; Role: PI
  7. Basement Membrane Targeted Nanoparticles for Post-Surgical Adhesion Prevention
    R01GM130590
    NIGMS, 02/01/2019 – 11/30/2022; Role: PI